Biotech Values

[jq1234]

>> Patients treated with 300 mg of ISIS-FXIRx experienced a seven-fold (p<0.0001) lower incidence of VTEs compared to patients treated with enoxaparin. Patients treated with 200 mg of ISIS-FXIRx had comparable incidence of VTEs compared to patients treated with enoxaparin.

Does 100mg difference - 300 vs 200 - really make 7-fold difference in efficacy? I doubt it unless there is another dose level for reference.